

LIST OF TABLES

Table		Page
1	Demographic characteristics of subjects receiving 1000 mg dosage of cefoxitin.	15
2	Demographic characteristics of subjects receiving 1000 mg dosage of ceftazidime.	16
3	Precision of the HPLC analytical procedure of cefoxitin.	20
4	Percent recovery of cefoxitin from serum following the extraction procedure.	21
5	Precision of the HPLC analytical procedure of ceftazidime.	24
6	Percent recovery of ceftazidime from serum following the extraction procedure.	25
7	Amount of cefoxitin measured in 6 vials of Cefoxin® and 6 vials of Cefxitin®.	27
8	Amount of ceftazidime measured in 6 vials of Fortum® and 6 vials of Cef-4®.	28
9	Mean plasma concentrations of cefoxitin at each sampling times after intramuscular administration of 1000 mg of Cefoxin® and Cefxitin® in twelve healthy volunteers.	30
10	Comparison of cefoxitin pharmacokinetic parameters after intramuscular administration of 1000 mg Cefoxin® and Cefxitin® in twelve healthy volunteers.	32

	Page
11 Mean plasma concentrations of ceftazidime at each sampling times after intramuscular administration of 1000 mg of Fortum® and Cef-4® in twelve healthy volunteers.	34
12 Comparison of ceftazidime pharmacokinetic parameters after intramuscular administration of 1000 mg Fortum® and Cef-4® in twelve healthy volunteers.	36
13 Comparison of pharmacokinetic parameters of cefoxitin in healthy volunteers between present and previous studies.	40
14 Comparison of pharmacokinetic parameters of ceftazidime in healthy volunteers between present and previous studies.	42

LIST OF ILLUSTRATIONS

Figure		Page
1	Structure of cefoxitin.	4
2	Structure of ceftazidime.	8
3	Typical chromatogram of cefoxitin in the serum after an extraction procedure before and 1.5 hr after intramuscular administration of cefoxitin.	20
4	Typical chromatogram of ceftazidime in the serum after an extraction procedure before and 15 min after intramuscular administration of ceftazidime.	23
5	Mean plasma concentration-time curves after 1000 mg intramuscular dosage of Cefoxin® and Cefxitin®.	31
6	Mean plasma concentration-time curves after 1000 mg intramuscular dosage of Fortum® and Cef-4®.	35

LIST OF ABBREVIATIONS

%CV	= percent coefficient of variation
°C	= degree Celsius
µg	= microgram
µl	= microliter
µm	= micrometer
ALT	= alanine aminotransferase
AST	= aspartate aminotransferase
AUC _{0-∞}	= area under concentration-time curve from administration and extrapolation to infinity
BUN	= blood urea nitrogen
Cl	= plasma clearance
cm	= centimeter
C _{max}	= maximal plasma concentration
dl	= deciliter
F _{rel}	= relative bioavailability
Hb	= hemoglobin
Hct	= hematocrit
HDTA	= hexadecyltrimethylammonium bromide
HPLC	= high performance liquid chromatography
hr	= hour
i.d.	= internal diameter
K _a	= absorption rate constant
K _e	= elimination rate constant

kg	= kilogram
L	= liter
M	= molar
mg	= milligram
min	= minute
ml	= milliliter
mm	= millimeter
nm	= nanometer
rpm	= round per minute
SD	= standard deviation
$t_{1/2}$	= half-life
T_{max}	= time to reach the maximal plasma concentration
u/L	= unit per litre
V_d	= volume of distribution
WBC	= white blood count
yr	= year

TABLE OF CONTENTS

	Page
ACKNOWLEDGEMENT	iii
ENGLISH ABSTRACT	iv
THAI ABSTRACT	vi
LIST OF TABLES	viii
LIST OF FIGURES	x
LIST OF ABBREVIATIONS	xi
INTRODUCTION	1
LITERATURE REVIEW	4
1. CEFOXITIN	4
2. CEFTAZIDIME	8
OBJECTIVES	12
MATERIALS AND METHODS	13
1. SUBJECTS	13
2. STUDY PLAN AND METHOD OF DRUG ADMINISTRATION	13
Cefoxitin administration and serial blood sampling	14
Ceftazidime administration and serial blood sampling	17
3. ANALYTICAL METHODS	17
Analytical method of cefoxitin	17
Analytical method of ceftazidime	21
4. PHARMACOKINETIC ANALYSIS	25
5. STATISTICAL ANALYSIS	26

	Page
RESULTS	27
- <i>In vitro</i> quantitative studies	27
-Bioequivalence Testing and Pharmacokinetic Studies	29
DISCUSSION	37
- <i>In vitro</i> quantitative studies of cefoxitin and ceftazidime	37
-Bioequivalence testing of intramuscular cefoxitin (Cefxitin® vs Cefoxin®) and ceftazidime (Cef-4® vs Fortum®)	37
-Pharmacokinetic study of cefoxitin and ceftazidime	38
CONCLUSION	43
REFERENCES	44
APPENDIX	51
VITA	54